2022
Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference
Pashankar F, Hanley K, Lockley M, Stoneham S, Nucci MR, Reyes-Múgica M, Elishaev E, Vang R, Veneris J, Rytting H, Olson T, Hazard K, Covens A, Arora R, Billmire D, Al-Ibraheemi A, Ulbright TM, Frazier L, Hirsch MS. Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference. European Journal Of Cancer 2022, 173: 59-70. PMID: 35863107, DOI: 10.1016/j.ejca.2022.06.006.Peer-Reviewed Original ResearchConceptsOvarian immature teratomaImmature teratomaGerm cell tumor elementsSerum alpha-fetoproteinGerm cell tumorsYolk sac tumorSerum tumor biomarkersForm of sarcomaTherapeutic dilemmaSac tumorRare subtypeSomatic malignancyCell tumorsNeuroectodermal elementsNeuroectodermal componentConsensus conferenceAlpha-fetoproteinTumor elementsManagement dilemmaAdult womenPractice differencesTumor biomarkersTeratomaTumorsClinicopathologic conference
2018
Ovarian Yolk Sac Tumors; Does Age Matter?
Conter C, Xia C, Gershenson D, Hurteau J, Covens A, Pashankar F, Krailo M, Billmire D, Patte C, Fresneau B, Shaikh F, Stoneham S, Nicholson J, Murray M, Frazier AL. Ovarian Yolk Sac Tumors; Does Age Matter? International Journal Of Gynecological Cancer 2018, 28: 77-84. PMID: 29194189, DOI: 10.1097/igc.0000000000001149.Peer-Reviewed Original ResearchConceptsOvarian yolk sac tumorEvent-free survivalYolk sac tumorOverall survivalSac tumorClinical trialsOvarian germ cell tumorsPreoperative alpha-fetoprotein levelAge cut pointStage IV diseaseAdverse prognostic factorPlatinum-based chemotherapyAlpha-fetoprotein levelsCut pointsGerm cell tumorsPediatric clinical trialsRisk of eventsOptimal cut pointJoint pediatricChemosensitive tumorsChemotherapeutic regimenPrognostic impactPrognostic factorsAdult trialsGynecologic oncologists
2017
Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study
Dicken BJ, Billmire DF, Krailo M, Xia C, Shaikh F, Cullen JW, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Rescorla FJ, Egler RA, Ross JH, Rodriguez‐Galindo C, Frazier AL. Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study. Pediatric Blood & Cancer 2017, 65 PMID: 29286555, PMCID: PMC6219870, DOI: 10.1002/pbc.26913.Peer-Reviewed Original ResearchConceptsOvarian germ cell tumorsMalignant ovarian germ cell tumorsGerm cell tumorsEvent-free survivalNon-GD patientsOverall survivalGonadal dysgenesisMalignant germ cell tumorsAggressive chemotherapy regimenHigh-risk groupNondysgerminomatous tumorsChemotherapy regimenPure dysgerminomaPediatric patientsSac tumorBilateral gonadectomyCell tumorsWorse outcomesEmbryonal carcinomaPatientsStreak ovariesDysgenetic gonadsTumorsY chromosome materialGonadoblastomaGerm Cell Tumors of the Ovary
Matei D, Frazier A, Hurteau J, Pashankar F. Germ Cell Tumors of the Ovary. 2017, 518-532. DOI: 10.1002/9781119196235.ch35.Peer-Reviewed Original ResearchGerm cell tumorsOvarian germ cell tumorsCell tumorsNondysgerminomatous germ cell tumorsPrimitive germ cell tumorsMixed germ cell tumorCornerstone of treatmentYolk sac tumorPrinciples of diagnosisLong-term toxicityQuality of lifeCurrent multidisciplinary approachLonger life expectancyNongestational choriocarcinomaHistological typeSac tumorRare tumorEmbryonal carcinomaMost womenTumorsYoung womenLife expectancyMultidisciplinary approachWomenTreatment